KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Invested Capital (2016 - 2026)

Palvella Therapeutics has reported Invested Capital over the past 10 years, most recently at -$93.8 million for Q4 2022.

  • Quarterly Invested Capital fell 284.76% to -$93.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$93.8 million through Dec 2022, down 284.76% year-over-year, with the annual reading at -$93.8 million for FY2022, 284.76% down from the prior year.
  • Invested Capital was -$93.8 million for Q4 2022 at Palvella Therapeutics, down from $44.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $55.3 million in Q2 2018 and troughed at -$93.8 million in Q4 2022.
  • The 5-year median for Invested Capital is $46.7 million (2020), against an average of $35.9 million.
  • Year-over-year, Invested Capital soared 1002.65% in 2018 and then crashed 284.76% in 2022.
  • A 5-year view of Invested Capital shows it stood at $39.9 million in 2018, then increased by 28.59% to $51.4 million in 2019, then crashed by 39.58% to $31.0 million in 2020, then surged by 63.58% to $50.8 million in 2021, then crashed by 284.76% to -$93.8 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Invested Capital are -$93.8 million (Q4 2022), $44.4 million (Q2 2022), and $53.4 million (Q1 2022).